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Catheter-associated blood stream infections (CABSIs) are serious, yet common, outcomes in both 
human and animals with indwelling catheters. The increasing rate of these infections is partially due to 
hindered knowledge on how to stop the spred of these pathogens, this due, in part, to inadequate animal 
models. Current experimental models fail to mimic various aspects of sepsis pathogenesis, diverse 
clinical symptomology, and in most cases lack the ability to test novel therapies for use in human 
medicine. In response to the urgent need for a more clinically relevant animal model of CAS, this large 
animal model was conceptualized and validated through this prospective study. Eight clinically healthy 
domestic cross-bred mature female sheep were obtained and double-lumen peripherally inserted central 
catheters (PICCs) were nonsurgically placed in the left jugular veins. A novel inoculation method was 
developed using a luminal volume of Klebsiella pneumoniae subsp. pneumoniae 43816RifR isolate and 
blood mixture (1:3). The mixture was injected into the lumen and was allowed to clot where is remainded 
for the duration of the study, enabling the development of a chronic catheter infection with the slow 
prolonged release of bacteria. This continual shedding of bacteria more closely mimicks the natural 
pathogenesis of catheter-associated sepsis (CAS) in clinical settings. A diverse yet dose-dependent host 
immune response was observed including; tachypneas, tachycardias, pyrexias, leukopeneas, 
neutrophilias, thrombocytopenias, hyperlacemias, and in some sheep biochemical signs of organ 
injury/damage with SOFA scores reaching ≥5. All challenged sheep fulfilled clinical sepsis criteria, as 
well as acute sepsis-induced organ injury and sepsis-induced coagulopathies to varying degrees. At 
necropsy all challenged animals showed evidence of recent bacteremia, acute organ injury and positive 
cultures of the parent 43816RifR isolate from several tissues, organs and catheters. In contrast, none of 





43816RifR isolate. Validation of this novel in vivo animal model of catheter-associated sepsis 
demonstrates its potential to serve as a robust, reproducible and reliable platform for future biomedical 
sepsis research.  
 
Introduction: 
Despite the historical significance of sepsis in human medicine, it remains one of the least understood 
and most enigmatic disease processes to date. It is not only hard to properly diagnose and treat, but until 
recently was best defined only by its clinical presentation [1-3]. This is due, in part, to highly 
heterogeneous intrinsic factors including; genetics, age, race, sex and health/comorbidities [4-7]. In 
addition, there are several extrinsic factors including treatment type, infection type, microbe(s), degree 
of insult, and time of infection [8-10]. Due to this multifaceted and highly varied host immune response 
[11-13], an intricate understanding of the complex pathophysiology of sepsis has not been fully 
described. This gap in knowledge hinders our ability to develop better diagnostics, therapies, and 
prevention methods.  
Animal models are an essential component in biomedical and sepsis research,  enabling investigators 
to study the molecular and cellular pathology of sepsis in experimental designs not feasible in human 
patients. However, current animal models of sepsis are subject to critique regarding the clinical 
translation of experimental data to human clinical sepsis [4, 7, 14-23]. While they provide an extremely 
valuable resource for studying the pathophysiology of several types of sepsis [4, 9, 18, 19, 21-24],  
current animal models of sepsis are limited in their ability to provide clinically relevant data specific to  
catheter-associated septicemias (CAS). In fact, several recent publications have argued that the use of 
animal models, particularly murine models, have resulted in significant misinterpretation and failure of 





Murine models often fail to properly reproduce clinical symptoms of human sepsis due to significant 
differences in the host-species tolerance for lipopolysaccharide (LPS), a key mediator of the 
inflammatory cascade associated with sepsis [25, 26]. In addition, most species used in current models 
are hindered by an inability to non-surgically place and maintain long-term intravenous catheters, 
repeatedly sample large volumes of blood, monitor clinical parameters (hemodynamic, 
cardiopulmonary, biochemical, etc.), or administer IV therapies or fluids to test current and novel 
treatments. There is a substantial need for the development of robust large animal models that more 
closely mirror the pathogenesis, immunology and pathophysiology of sepsis.  
Similar to human internist, large animal internal medicine specialists routinely deal with sepsis and 
bacteremia in hospitalized horses, sheep, goats and cattle. Like humans, the source of infection is often 
associated with long-term IV catheterization. The use of sheep as an animal model of sepsis has been 
suggested in several articles [17, 21, 27-33], and the similarities in body size, anatomy, immunology and 
pathophysiology make them an ideal species for studying human disease processes. Sheep can be easily 
acquired and housed, have a proven track record in human biomedical research, and are amenable to a 
full array of advanced medical diagnostics and monitoring [27, 31, 34]. They provide marked advantages 
over swine in that we can easily place and maintain peripherally inserted intravenous central catheters 
(PICC) and urinary catheters without surgery or sedation, can be administered continuous rate infusions 
of IV fluids or antibiotics, and they are much more easily handled for evaluation of blood pressure, 
echocardiography and closed-system urinary catheter collection . In addition, they have LPS sensitivities 
similar to humans, and have similar pharmacokinetics/pharmacodynamics to many antibiotics used in 
humans, such as carbapenems [26-28, 33]. There are currently several validated ovine models simulating 
the critical care situation in humans, and they arguably are much more clinically relevant to study 





Current literature states that up to 90% of patients admitted into hospitals will require some type 
of vascular access to deliver intravenous (IV) medication, blood products, and/or fluids [35-42]. Among 
these catheterized patients, an estimated 40% will require a centrally placed vascular access point 
commonly referred to as a central venous catheter (CVC) or more commonly in human medicine, a 
central-line (CL) [43, 44]. CVCs are a necessity for the proper care of critically or chronically ill 
individuals, as they are required for infusion of certain medications (due to toxicities, volume, etc.), 
nutritional support, fluid replacement, blood collection, renal replacement therapy, and hemodynamic 
monitoring [39, 43, 45-49]. However, despite their significant benefits to public health, and the millions 
of lives they save every year, there are substantial risks involved with their use.  
Catheter-associated blood stream infections (CABSIs) have various etiologies, but disease usually is 
initiated as a monomicrobial infection of the catheter lumen. These infections of the catheter lumen form 
a biofilm and seed a long-term systemic infection (sepsis). Many CABSIs and CAS are caused by 
members of the Enterobacteriaceae family, including Klebsiella pneumoniae subsp. pneumoniae [50, 
51].  
Our a priori hypothesis for this study was that the intraluminal seeding of Klebsiella pneumonia in 
central intravenous catheterized sheep would result in a dose-dependent host immune response that 
would fulfill the criteria of sepsis in humans (both Sepsis-2 and Sepsis-3 definitions) [1-3]. In addition, 
confirming the ease of placement and ability to maintain a double lumen peripherally inserted central 
catheters (PICC) in sheep without the use of general anesthesia of sedation. Successful proof-of-concept 
induction of sepsis in sheep using this novel induction method combined with the ability to collect 
frequent samples of large volumes of blood provides a much needed platform on which to further 






Materials and Methods: 
Animal preparation and general experimental design/setup. Eight adult domestic crossbred 
clinically healthy female sheep were obtained and housed in the livestock infectious disease isolation 
facility at Iowa State University. The average body weight for the animals was approximately 70 kg at 
the start of study. The sheep were housed in individual pens, with control groups physically separated 
from the challenge groups. The sheep were allowed four days for acclimatization to their new 
environment prior to the initiation of the experimental procedures. All subjects were fed identical diets 
of free choice grass hay and a ruminant concentrate pellet twice daily and were given free access to clean 
water at all times. The eight ewes were randomly placed into three groups; Control Group (N=2), 
Challenge Group #1 (N=3) and Challenge Group #2 (N=3). During the course of the study, each of the 
challenge groups received two inoculations, with the second challenge occurring after the return to 
baseline cardiovascular and physiologic parameters following the first dose. On day 0 of the study, all 
ewes were administered their first inoculation (all subjects inoculated within 1 hour of each other).  
Challenge group #1 received (Dose #1 of 103 CFU) K. pneumonia 43816RifR isolate while challenge 
group #2 received (Dose #2 of 107 CFU) of the K. pneumonia 43816RifR isolate. The control group 
received sterile bacterial media (TSB) as a sham inoculation. In order to assure that physiological 
parameters returned to baseline prior to re-challenge, the second inoculation was administered at 
different time points for the challenge groups. On day 7 of study, challenge group #1 received (Dose #3 
of 108 CFU) K. pneumonia 43816RifR isolate, while challenge group #2 received (Dose #4 of 109 CFU) 
K. pneumonia 43816RifR isolate on day 12 of the study. Beginning two days prior (day -2) to the first 
inoculation and continuing through the study endpoint, physiologic assessments were performed, and 





Animal Welfare Assessments. The Iowa State University Institutional Animal Care and Use 
Committee approved all of the experiment protocols in this study under protocol 3-15-7965-O. Based 
on the recommendations of a recent publication regarding the development and refinement of animal 
models of sepsis [52, 53] we elected to limit the treatment group sizes in lieu of trying to achieve 
statistical significance. As argued by that publication, this study was designed as a descriptive proof-of-
concept effort [53].  In addition, in order to assure humane endpoints for animal euthanasia we developed 
and the IACUC approved a monitoring algorithm (Appendix I). This algorithm included a four-level 
score for each of the following parameters: activity, head position, breathing pattern, rectal temperature, 
hydration status, heart rate, eating and ability to stand. Scores for each parameter were recorded twice 
daily beginning two days prior to the first inoculation through the duration of the study, with more 
frequent evaluations immediately following the highest dose challenge of 109 CFU (every 15 minutes 
for two hours, then every hour for five hours). Sheep receiving a severity score of four in six or more of 
the assessed parameters would be euthanized immediately.  
Preparation of bacteria. Klebsiella pneumoniae subsp. pneumoniae (Schroeter) Trevisan (ATCC® 
43816™) serotype 2, was the inoculum strain used throughout this study. In order to allow for easier 
monitoring, the parental ATCC 43816™ strain was sub cultured (109 CFU) onto a Trypticase soy agar 
(TSA) plate containing 100 ug/ml rifampin. An ATCC 43816 Rifampin resistant (43816RifR) isolate 
was selected and isolated, then stored for use throughout study (MIC to rifampin > 256 ug/ml).  
Central intravenous (PICC) catheter placements. Intravenous catheters identical in material and 
placement to catheters used in long-term IV catheterization in humans were selected. These double-
lumen (2x18 gauge) wire guided long-term Mila silicone peripherally PICC inserted central catheters 
(Mila order #3565) were placed in the left jugular vein of each ewe. Prior to insertion of the catheters, 





aseptically (Povidone/Iodine) along the jugular vein. Maximal sterile barrier precautions were used as 
described in [47] to avoid contamination of the catheters. Catheter placement did not require general 
anesthesia or sedation, however 1.5ml of 2% lidocaine solution was injected subcutaneously at the site 
of catheter placement to provide local anesthesia. The appropriate catheter length was estimated by 
measuring the distance from the site of insertion to the approximate site of the distal vena cava or right 
atrium (as is typical for central catheters in humans) and aseptically cut to length according to 
manufacturer. Catheters were secured using 2-0 suture and needleless injection ports (Mila order #8095) 
were placed on each line. Once catheters were placed and secured, both ports were flushed with 10ml 
heparinized saline solution and tested for patency. Thereafter, 10ml heparinized saline solution was 
administered after each sample collection and twice daily to ports that were not sacrificed for inoculation. 
Sample collection and cultures. Approximately 20ml blood samples were obtained daily from the 
second catheter lumen following standard aseptic preparation. Samples were aliquoted as necessary for 
the testing required at the given sample period. Initially blood culture methodology utilized a low volume 
of blood (1 mL) directly applied to the culture media as a spread plate. However, following inoculation 
#1, absence of growth in cultures of the isolates was observed in all blood or fecal samples collected. As 
a result, on day 7 (Dose #3) of the experiment, the decision was made to increase the volume to 5 mls of 
blood and adding enrichment to cultures to facilitate the growth of the 43816RifR isolate in-vitro. The 
enrichment of blood samples was performed by adding 5 ml of blood samples into 50 ml TSB broth 
containing 100 ug/ml rifampin. These enriched samples were incubated at 37 ºC overnight and 250 ul of 
culture was spread out uniformly on TSA + Rifampin plates. Broth and agar plates for cultivation of K. 
pneumoniae 43816RifR isolate included tryptic soy agar + 100 ug/ml vancomycin + 100 ug/ml rifampin 
to quantitatively culture the blood and fecal samples. Fecal samples were obtained from rectum using 





performed as described above. Select tissue and catheter samples were cultured following necropsy. For 
samples not receiving the enrichment step, CFU counts were obtained by physical counts of colonies on 
selective media. When enrichment was performed, samples were recorded as positive or negative 
without quantification. 
Cardiovascular, hematological and coagulation profile monitoring. Heart and respiratory rates were 
obtained by auscultation and visual observation of thoracic cavity for movement from inhalation. Two 
methods were used for temperature monitoring. First, rectal temperatures were obtained by inserting a 
digital thermometer approximately 3 inches into rectum and pressing tip gently against rectal wall. 
Secondly, rumen temperature data loggers (iButton) were administered via oral bolus for continuous 
temperature monitoring and were recovered at necropsy. Blood samples were collected from the second 
catheter lumen in the jugular vein and placed into vacutainers containing EDTA and sodium citrate as 
anticoagulants or into serum tubes (free of anticoagulant) for biochemical analysis. Hematological and 
serum samples were placed at 4ºC and analyzed by an accredited veterinary clinical pathology laboratory 
(Iowa State University College of Veterinary Medicine) within 4 hours of collection. Complete blood 
counts (CBCs) were monitored daily for the first week of the study and during intensive monitoring of 
high dose challenge (dose #4), then every other day thereafter. Serum chemistry was analyzed every 
other day throughout the study and banked for future analysis. Complete coagulation profiles including 
D-Dimers, prothrombin (PT) and partial thromboplastin (PTT) times were performed intermittently 
during the study when evidence of sepsis induced coagulopathies (such as; signs of petechia, 
dehydration, and/or mottling of the skin).  
Inoculation #1. Dose 1 (~1x103 CFU into three ewes in challenge group #2) and Dose 2 of (~1x107 
CFU into three ewes in challenge group #1) were administered by “sacrificing” a single lumen of each 





In all ewes, the K. pneumoniae 43816RifR isolate (resuspended in 100 ul of broth) was mixed with 300ul 
of fresh blood collected from the animal by inversion of the syringe. The 400ul of mixed blood/inoculum 
was then injected back in the lumen allowing it to fill the lumen without injecting into the bloodstream. 
The blood was then allowed to clot, resulting in the occlusion of a single catheter lumen contaminated 
with a monoculture of K. pneumoniae 43816RifR isolate. By utilizing a single lumen of the catheter to 
serve as a reservoir for microbial growth it enabled the prolonged shedding of a monoculture of bacteria 
from the contaminated catheter, which is a key element to the overall pathogenesis and pathobiology 
seen in many types of catheter associated sepsis. Since no previous sheep models have used a similar 
method of inoculation of this pathogen, the doses were empirically selected. After inoculation, the lumen 
port that received the inoculations was closed and sealed with red tape labeled “inoculation port” and 
remained undisturbed throughout the remainder of the study.  
Inoculation #2. Dose 3 (~108 CFU to the three ewes previously given Dose #1 in Challenge Group 
#1) and Dose 4 (~109 CFU to the three ewes previously given Dose #2 in Challenge Group #2) were 
subsequently administered due to neither of the first two inoculation doses resulting in sufficient changes 
in clinical signs indicative of severe sepsis.  This approach minimized animal usage (consistent with 3R 
approach to developing animal models) while maximizing our data collection on dose responses. These 
second dose inoculations of the K. pneumoniae 43816RifR isolate were given to both challenge groups 
using the same technique as Dose 1, with the exception of using the second lumen of the double lumen 
catheter. Challenge group #1 was inoculated a second time on day 7 and challenge group #2 was 
inoculated a second time on day 12.  
Euthanasia. No sheep were euthanized due to meeting the criteria outlined in our endpoint’s 





10 mls pentobarbital sodium (Fatal Plus© 390 mg/ml) into the jugular vein.  The control group and 
challenge group 1 were euthanized on day 14, while challenge group 2 was euthanized on day 15.  
Necropsy. A board-certified veterinary pathologist performed a gross necropsy immediately after 
death was confirmed for each ewe. Tissue samples collected from various organs were swabbed with a 
sterile, dry swab and/or placed in a sterile tube for microbiological evaluation or 10% neutral buffered 
formalin solution for histological analyses. Swabs were taken aseptically from lungs, liver, catheter, 
spleen, heart valves, feces, duodenal contents, and arterial blood. These swabs were cultured on selective 
media for K. pneumoniae 43816RifR isolate growth as described above. Tissue samples were collected 
from lung, liver, spleen, and heart valves for histopathology. The hearts were checked grossly for any 
evidence of endocarditis. Lastly, the (iButton) rumen temperature data loggers were retrieved from the 
rumen or reticulum of the subjects.  
 
Results 
Dose-Dependent Host Immune Response. The sheep demonstrated a dose dependent host response 
that displayed consistency with the pathophysiology of sepsis and satisfies the clinical criteria used to 
define human sepsis, including what was previously considered severe sepsis and septic shock (tables 1-
2 and figs. 1-3). Additionally, the severity of sepsis was approximated using human (SIRS and SOFA) 
criteria and the model successfully induced disease states meeting various levels of these criteria in sheep 
at specific time intervals of the study (tables 1-2 and figs. 1-3). Clinical signs consistently observed in 
individual animals following inoculation #1 (Dose #1 & Dose #2) included tachycardia, pyrexia, 
tachypnea, neutrophilia, leukocytosis, thrombocytopenia, increased total bilirubin and hyperlactemia. A 
dose-dependent response was observed, with higher doses having a more profound physiologic response 
in the measured parameters. While the general trends in physiologic response were fairly consistent 





response. For example, a much more robust immune response was seen in all subjects within challenge 
group #2 following Dose #4. In addition to the clinical signs mentioned at the lower doses, these animals 
demonstrated changes in hematological markers including leukocytosis, lymphocytosis, neutrophilias, 
neutrophil bands, thrombocytopenia, increased PT, PTT and D-Dimers.  The last four findings are 
consistent with dessiminated intravascular coagulation. Variable changes in biochemical indexes were 
also seen in these animals with increased serum BUN, lactate, serum creatinine, bilirubin, AST and GGT. 
Following the highest inoculatioin dose (Dose 4) physiologic changes consistent with human SOFA 
diagnostic criteria, as well as SIRS, were observed. Lastly, given that each of these animals had a known 
site of infection (contaminated catheter), all of the animals would meet the human criteria for clinically 
sepsis, with variable severity correlated to the inoculation dose.  
Sham Inoculation (Dose 0): There were no clinical signs of any type of infection observed at any 
timepoint for either of the two control sheep. There was a notable variability in rumen temperatures 
during different parts of the day (eating, circadian rhythm) [54], and specifically after drinking cold 
water (significant changes in temperature at a few timepoints in all sheep were affected by this). Lastly, 
on average the rumen temperatures were ~.8⸰C higher than all of our recorded rectal temperatures. 
However, this is a well documented phenomenon [54].  
Dose #1: 1x103 CFU. Challenge group #1 received their first inoculation dose of ~103 CFU on Day 
0 of experiment. No significant changes in heart rate, respiratory rate, rumen/rectal temperature, 
leukocytosis, or neutrophil counts were observed following initial inoculation (fig. 1a-c,f).  However, 
there was an undulant fever present in all three ewes starting 3 days post inoculation of this dose. This 
is more notable when analyzing the continuously acquired rumen temperature data and was largely 





we observed intermittent tachycardias, tachypneas, slight increases in serum lactate, mild leukocytosis’ 
at later time points (fig 1a-c, f) and increased total bilirubin (table 2, Appendix VI). 
Dose #2: 1x107 CFU. Challenge group #2 received their first inoculation dose of ~107 CFU on Day 
0 of experiment. We observed significant pyrexias (fig. 2a), tachycardias (fig. 2b), tachypneas (fig. 2c), 
leukocytosis, lymphocytosis, and significant neutrophilias (fig. 2f). The severity of clinical signs slightly 
varied among individual subjects, but for most parameters lasted for 3-4 days post inoculation (fig. 2a-
f). The neutrophilia peaked at one day post-inoculation and increased from a pre-inoculation 
concentration of ~4 x107/ul (+/- 1 x107) to ~10 x107/ul (+/- 2 x107) (fig. 2f, Supplemental VI). Extreme 
thrombocytopenias were observed post challenge Dose #2 in Ewe #3 on day 1 and day 2 of 60 x103/ul 
and 59 x103/ul, respectively (fig 2e). 
Dose #3: 1x108 CFU. Challenge group #1 received their second inoculation dose of ~108 CFU on 
Day 7 of experiment. Immediately following this inoculation, pyrexias (fig. 1a) and tachycardias (fig. 
1c)  were observed. There was only a slight increase in the respiratory rates following this dose challenge 
(fig. 1b). In addition, there were pronounced leukocytosis’,  hyperlactemias (fig. 1d), neutrophilias, (fig. 
1f) and thrombocytopenia (fig. 1e) observed during the few days post inoculation through the termination 
of the experiment.  
Dose #4: High Dose inoculation 1x109 CFU. Challenge group #2 received their second inoculation 
dose of ~109 CFU on day 12 of the experiment. Clinical presentations were similar to dose #2 that they 
received 12 days earlier; however, they were more intense and manifested several additional physiologic 
changes consistent with more severe host immune response to the systemic infection. Observed were 
acute pyrexias (fig. 2a), tachycardias (fig. 2b), tachypneas (fig. 2c), leukocytosis, significant 
neutrophilias (fig. 2f) and extreme thrombocytopenias (fig. 2e). These thrombocytopenias are observed 





the high dose intensive monitoring (fig. 3a-d) displays these physiological changes in more clarity and 
demonstrates the hyperlactemias observed (fig. 2d, 3d). Band neutrophils were seen increasingly from 
day 13 through 15 until euthanasia in Ewe #4 (.0726, .2512, .3699 x103/ul, respectively). Further 
indication of sepsis, or sepsis induced organ injury/failure were observed including increased BUN from 
a baseline of ~11mg/dl on day #12 to 16, 31 and 22 mg/dl in ewes 3-5 on day #13, respectively. Serum 
Creatinine (SCr) increased from an average baseline of ~0.9 mg/dl in all groups (N=8), to ~1.25 mg/dl 
(N=3). Increased bilirubin in ewe #4 was seen from an average of ~.6mg/dl before dose #4, to 1.17mg/dl, 
.75mg/dl on days 13 and 14, respectively. Additionally, there were significant changes in MPV, 
monocytes, AST, fibrinogen, PT, PTT, D-Dimer that were observed with varying intensities and 
durations (Supplemental I, Appendix VI). 
Qualitative/Quantitative Blood and Fecal Cultures. On Days -1 and 0 (pre-inoculation), all cultures 
for K. pneumoniae in blood and fecal samples from sheep were negative. The daily blood and fecal 
samples from days 0 through day 7 (post-inoculation #1, Doses #1 & 2) were tested for 43816RifR isolate 
in all control and challenge ewes. However, there was no bacteria recovered for any of the samples 
during this time period. Following the change to a higher inoculation volume and the addition of an 
enrichment step, all ewes had at least one blood sample positive for the 43816RifR isolate following their 
second challenge dose. Blood and fecal cultures from challenge group #2 on days 13-15 had positive 
cultures for the 43816RifR isolate. Culture of the intravascular tip of the PICC catheter collected at 
necropsy confirmed that all but one challenge inoculated catheters were culture positive for the 
inoculated K. pneumoniae. Liver, blood, and spleen samples collected during necropsy yielded no 
growth of K. pneumoniae in all eight sheep.  Lung swabs collected at the site of gross lung lesions for 





a positive culture of intestinal content (~2000 CFU) at necropsy. The control group sheep remained 
culture negative for the K. pneumonia 43816RifR isolate throughout the study. 
Gross Histology/Histopathology. No remarkable gross or histopathologic lesions were observed in 
any thoracic or abdominal viscera of the control group. In contrast, all animals in both challenge groups 
demonstrated varying degrees of multifocal to coalescing gross lung lesions ranging in size from 0.1-4.5 
cm in diameter (fig. 4a). Histopathologic evaluation of these lung lesions revealed a consistent fibrinous 
and seroproteinaceous pneumonia, progressing in more severe cases to a marked multifocal suppurative 
inflammation with an associated segmental vasculitis and fibrin thrombi (fig 4a). Ewes 3, 7 and 8 had 
serofibrinous lesions with neutrophils in lung suggestive of acute inflammation. Ewe #8 had a significant 
vessel with a thrombus and fibrinosuppurative vasculitis. In addition, a single animal demonstrated a 
moderate lymphocytic periportal hepatitis (Supplemental I). All three ewes in challenge group #1 (Dose 
#1, and Dose #3) had a subjective splenomegaly. The multifocal pathology in the lung was found 
predominantly in the middle and caudal ventral lung fields (lesions were not typical of sheep pneumonia 
and instead were consistent with septic bacterial emboli lung (fig. 4b) and were markedly different from 
the controls.  As expected, animals receiving the highest bacterial doses of 107 CFU (Dose #2) and 109 
CFU (Dose #4) had the most significant lesions at necropsy (figs. 4a-b). These findings suggest a well-
established systemic infection in all challenged ewes.  
 
Discussion: 
In this study, the observed host immune responses to Klebsiella pneumoniae induced catheter 
associated sepsis in sheep demonstrate clinically relevant and translational similarities to that of humans. 
The onset of clinical symptoms includes dose-dependent changes in respiratory, cardiovascular, 





the well-documented symptoms of sepsis, septic shock, sepsis-induced acute organ injury and sepsis 
induced DIC seen in humans [1-3, 55-63]. The novel inoculation method described in this study utilizes  
monomicrobial bacteria intraluminally seeding of the catheter to better replicate the mechanism of 
infection, etiology and pathobiology of CAS in humans. As the most common etiology of infection in 
catheterization is biofilm formation. The results of this study demonstrate that this ovine model of CAS 
offers a highly reproducible, reliable and clinically relevant research platform to further study sepsis and 
to test novel treatment approaches of clinically ill patients. Importantly, the model successfully induced 
the clinical criteria of sepsis in humans, by using both old and new definitions of sepsis (Table 2)[1-3]. 
Sepsis is currently the most expensive disease process treated in U.S. hospitals and its incidence is 
steadily increasing each year [64-67]. Additionally, severe sepsis affects more than one million 
Americans annually [41, 68], an estimated 28 to 57 percent of which die as a result [10, 69-71]. Catheter-
Associated bloodstream infections (CABSI) and subsequent Septicemias (CAS) are systemic infections 
that often involve a pathogen forming a biofilm within the catheter hub where it serves to seed a long-
term infection. Additionally, CABSIs are associated with the emergence of several antibiotic resistant 
pathogens that are nearly impossible to treat and have an additional increase in mortality rates of up to 
57% (71-73, 78-85, 99).  
Presentation of sepsis, and septic shock using both old Sepsis-1 and Sepsis-2 definitions (including 
SIRS symptoms) and the newest Sepsis-3 definitions including SOFA criteria (without SIRS symptoms) 
were observed and evaluated in this ovine model of CAS (table 2) [1-3]. The SIRS cardiovascular criteria 
include pyrexias, tachypenias, tachycardias, leukocytosis and were observed in a dose dependent manner 
with varying duration and severity [2]. Using only these cardiovascular symptoms, each challenged ewe 
met the criteria of SIRS with at least 2/3 criteria being met (pyrexia, tachpnea) [1-2] (table 2, fig 3a-c). 





temperature data (table 2, Appedix VI). These are especially evident during the high intensity monitoring 
of high dose (fig. 3a-d). Since there is a documented infection involved (bacterial contamination of the 
catheter), they are considered to be experiencing clinical sepsis (table 2). SIRS remained evident in each 
of the challenged ewes throughout the study. The newer SOFA based criteria of sepsis that deemphasizes 
SIRS was also satisfied by documenting changes of the following clinical symptoms, respiratory 
(tachypeneas), coagulation (thrombocytosis’), liver dysfunction (increased serum bilirubin), renal 
dysfunction (increased serum creatinine) and serum lactic acidosis (table 1-2, figs. 1-3) [3]. 
Consequently, the changes observed fulfilled the requirements for sepsis by several different definitions. 
Furthermore, since these clinical symptoms developed immedietly following the intentional induction 
of K. pneumonia in the catheter lumens, and none of the control sheep developed similar syptoms, we 
are confident that these symptoms were not from a secondary source (such as pre-existing ailments). In 
addition, several sheep displayed early signs of sepsis induced acute organ injury following the highest 
inoculation dose #4, which manifested as increased hyperlactemia, increased serum creatinine, increased 
AST, increased BUN, increased bilirubin, thrombocytopenias, tachypneas and tachycardias (tables 1-2, 
figs. 2-3),.  
Signs of disseminating intravascular coagulation (DIC). Further evidence of organ dysfunction 
includes the observed alterations in coagulation profiles, including disseminated intravascular 
coagulation (DIC), in a subset of animals with increased PT, aPTT and D-Dimer [72-75] (table 1). A 
rather diverse onset of clinical coagulopathies characterized by an increased fibrinogen levels, elevated 
D-Dimers, thrombocytopneas, prolonged activated partial thromboplastin time (PTT) and prothrombin 
times (PT) (table 1) were observed. These variable, yet dose dependent coagulation profiles observed 
are expected with these genetically diverse sheep with likely subclinical comorbidities, and previous 





in three separate sheep at two different time points, and likely serves as a catalyst in the initial stages of 
sepsis pathophysiology [49, 58, 73, 76-78]. Two sheep from challenge group #2 displayed extreme 
thrombocytopenias post challenge (Dose #2, inoculation #1) Ewe #3 (day 1 and day 2 of 60 x103/ul and 
59 x103/ul, respectively) and post challenge (Dose #4, inoculation #2) Ewe #4 (days 13-15 with 20 
x103/ul, 27 x103/ul, 36 x103/ul, respectively) (table 2, Appendix VI).  
Sepsis-induced tissue hypoperfusion. Tissues and organs receiving inadequate oxygen and nutrients, 
often resulting in injury during the early phases of sepsis. Several physiologic responses consistent of 
this syndrome are seen in challenge group #2 (primarily after high dose #4) including, tachycardia (fig. 
3b) and increased lactate levels (fig. 3d). These sepsis-induced tachycardias are likely due, in part to an 
increased capillary leakage, decreasing the venous return to the heart and cytokines released contribute 
to myocardial depression. Tachycardias lasting >1-day post dose #4 inoculation increased from an 
average baseline of ~85 BPM in all samples to ~120 BPM (fig. 2d, 3d). Elevated lactate concentrations 
were evident post high dose inoculations, with a 4-fold increase from a baseline of ~.6mMol to ~2.4 
mMol following dose #4 (1x109 CFU) on day 13 (fig. 2d, 3d). As suggested in the 2012 surviving sepsis 
campaign, increased lactate levels are a marker for tissue hypoperfusion ([10, 79-81]. Sepsis induced 
hyperlactemias are common in early tissue damage due to the aberrant oxygen flow to tissues and organ 
systems resulting in anaerobic respiration. Evidence of regional hypoperfusion is observed in several 
organ systems of the body including, renal dysfunction/injury manifest by increased blood urine nitrogen 
(BUN) and increased levels of serum creatinine (SCr) [79, 80, 82-86]. SCr increased from an average 
baseline of ~0.9 mg/dl in all groups (N=8), to ~1.25 mg/dl (N=3) following dose #4 (1x109 CFU) in 
challenge group #2 (table 2, Appendix VI). The increase in serum creatinine of +0.35 mg/dl  in less than 
24 hours post high dose challenge is a strong indicator of acute kidney injury (AKI) due to sepsis [84, 





classification system, an increase in serum creatinine levels if ≥.3 mg/dl from baseline levels within the 
first 24 hours of suspected sepsis is indicative of kidney injury/dysfunction and is a primary indicator in 
the prognosis of AKI [86, 88]. It is well documented that an elevated level of SCr is a strong indicator 
of AKI and linked to severe sepsis and septic shock [89]. Furthermore, in a cohort study by 
Vanmassenhove et al [90], the argument was advanced of using serum creatinine as an independent 
predictor of mortality, rather than a bystander in cases of sepsis induced AKI. Blood urea nitrogen 
(BUN), a SOFA criteria also showed a significant increase from an average baseline of ~13mg/dl to 
~22mg/dl one day post dose #4 inoculation in group #2 (table #2).  
Although, there were consistent trends observed as a function of the dose administered, the severity 
and duration of symptoms varied slightly between each ewe within a challenge group. This is an expected 
observation considering these sheep are outbred and genetically diverse. Similar to a diverse population 
of humans, the sheep displayed individual differences in host immune responses to the infection. This is 
an important point when considering that many murine models utilize inbred populations of mice, which 
sometimes fail to replicate the individual variation observed in human disease.  
Animal models, which closely reproduce the human condition, serve a vital role in the efficient 
development of preventative, diagnostic, and therapeutic strategies in various types of disease in humans. 
Currently, two murine models of sepsis are most commonly used in laboratory settings: the cecal ligation 
and puncture (CLP) model and the colon ascendens stent peritonitis (CASP) model [16, 53, 91]. They 
are currently considered the most credible animal models of sepsis, with CLP considered the gold 
standard for sepsis research, according to Lilley, et al.[53]. In the CLP model, the cecum of the mouse 
is ligated and then perforated using a needle allowing bacteria in the cecum to migrate into the abdomen 
and establishing a mixed polymicrobial bacterial peritonitis that progresses to sepsis[53, 91] While the 





continual passage of fecal material into the peritoneum, again resulting in a polymicrobial peritonitis. 
Although widely used and comparatively inexpensive, these mouse models have several significant 
shortcomings.  
First, they require general anesthesia and surgery, which have documented impacts on the host 
immune response and subsequent development of sepsis [16]. Second, while these models may replicate 
post-operative sepsis, they fail to replicate the most clinically relevant routes of exposure for emerging 
causes of sepsis, associated with the placement of indwelling central venous catheters, urinary catheters 
and mechanical ventilators. Third, these mouse models do not lend themselves to the standard medical 
interventions routinely utilized in human sepsis therapy, including IV therapies (drug, fluid replacement) 
and the frequent large volume blood collection for monitoring clinical parameters or allow testing of 
novel therapeutics. Fourth, the progression of the septic process in the mice often occurs more rapidly 
than in humans, with the mouse model often culminating in death after 3 days[16], while in humans a 
longer period of 2-3 weeks is commonly observed [8].  Fifth, unlike mice, which are several 1000-fold 
less sensitive to LPS than humans, sheep show similar sensitivities to LPS as humans [33]. Sixth, at a 
gene expression level, acute systemic inflammatory responses in mice appear to be quite different from 
that of humans [16, 21, 23, 53, 92]. And finally, even though sepsis in humans is, by and large, a disease 
that occurs at the extremes of age [4, 18-21] and the short lifespan and rapid maturation of mice limits 
the ability to study the role of age in the murine models.  
Collectively, these issues coupled with the concerns over how well the mouse immune system mimics 
the human disease process suggests a critical need for the development of new animal models of sepsis. 
In particular there is significant need for a model that more closely mimics the human development of 
CAS originating as a monomicrobial infection of nosocomial origins. To address this issue, several 





however these models also have significant shortcomings. As outlined in a review by Deitch (36), “The 
problems inherent with current sepsis models created through intravenous bacteria infusion are as 
follows: a) they do not correlate with clinical disease; b) they typically produce a hypodynamic 
circulatory response; c) survival time is generally short and therefore there is limited time for progression 
of disease; d) the serum cytokine response is transient and much greater in magnitude than that observed 
in septic patients; and e) antisepsis agents shown to be effective in these types of animal models have 
not been effective when tested in clinical trials.” In this manuscript we provide proof-of-concept 
evidence that these deficiencies can be overcome by utilizing a novel induction method that relies on 
seeding of a blood clot in a PICC without direct injection of bacteria into the bloodstream.  This approach 
allows for gradual and continual low level shedding of bacteria into the bloodstream, more closely 
mimicking CAS and resulting in a more prolonged event. 
Despite demonstrating physiologic evidence of sepsis, many of the blood samples collected remained 
culture negative, especially at the lower doses. Only animals in the higher dose groups (doses #3 and #4) 
were found to be blood culture positive following inoculation. In our initial efforts with the lower doses, 
we were only performing low volume (0.1 mL) direct culture of the blood, a technique that has low 
sensitivity. In human medicine it is routine to preform multiple large volume blood cultures over the 
course of a 24 hour period in order to demonstrate bacteremias. It is possible that by using the higher 
volume enrichment protocol adopted following dose 3 and 4 we would likely have been able to 
demonstrate blood culture positive results. This situation is consistent with that observed in human 
medicine, where according to current studies more than 50% of severe sepsis cases are culture 
negative[93, 94].  
Several additional benefits of the sheep model for future sepsis research were demonstrated in our 





the study allowing for the potential for concurrent administration of IV antibiotic infusions, fluid 
resuscitation, cardiotropic drugs or other therapeutic interventions.  These types of interventions are 
often difficult in the murine and porcine models since these species often require sedation or anesthesia 
when administering continuous rate IV infusions.  Second, the ability to easily collect frequent blood 
and urine samples allows concurrent pharmacokinetic monitoring during sepsis in order to evaluate the 
role that sepsis plays in altering pharmacokinetics and pharmacodynamics. 
Under recommendations of a recent report focused on balancing science with animal welfare, we 
elected to use only eight sheep, in order to minimize animal usage for our proof-of-concept model 
demonstration (3Rs) [53, 91]. The premise of this report advocates that new animal models of sepsis be 
developed using a minimal animal numbers in a proof of concept manner. The limited number of test 
subjects made statistical analysis unsuitable, however the consistency of the data provides compelling 
information regarding the benefit of the model in future studies. The dose-dependent response also 
provides a good starting point for decision making regarding the inoculation dose necessary to induce 
varying degrees of disease severity. We considered utilizing four independent groups of animals to 
evaluate the dose-dependency, however elected to reduce animal usage by using a second higher dose 
inoculation in each group of the animals.  While this does complicate some of the interpretation of the 
data, it still provides a strong foundation for future research design concerning appropriate dose and the 
expected variability between individuals. Therefore, the data presented here provides critical information 
for future power studies in similar studies.  
 There are several potential drawbacks to the approach we utilized in this study or to the use of sheep 
for sepsis research in general. First, the limited number of test subjects made statistical analysis 
unsuitable for interpreting the data, and thus was left out of this report. Future use of the model can easily 





generated here. Another potential drawback to using sheep is that as a ruminant species the use of oral 
antibiotics has the potential to be significantly impacted, however oral antibiotics are rarely used as first-
line choices in sepsis. In fact, previously published pharmacokinetic studies suggest that the sheep 
correctly modeled the human pharmacokinetics of many parenteral drugs of interest, included the 
carbapenems[28]. Finally, the duration of our study was limited, limiting the expected late onset of late 
phase sepsis and MODS as commonly seen in chronically catheterized human sepsis patients. Although 
we attempted to utilize oscillometric non-invasive blood pressure measurement as part of this study it 
was determined to be unreliable and inconsistent when applied to animals that were standing and 
occasionally moving. However, there are commercially available implantable telemetric invasive blood 
pressure, blood gas, and temperature monitoring systems that have been validated for use in sheep [34]. 
Also, perhaps the most important limitation to the use of ovine models, being the lack of validated 
reagents (including Procalcitonin, CRP, and other biochemical quantitative assays). However, this lack 
of reagents for use in ovine models will be solved, especially with the continued sequencing of the ovine 
genome [95], which will allow the rapid PCR of genes necessary for the manufacture of biological tools. 
Going forward. Instead of exhausting more billions of more dollars in funding, precious research 
time and inevitably patient’s lives, the use of a more clinically relevant species of sepsis is crucial to our 
understanding of the disease process. This has been a largely debated topic and remains largely 
unsolved/unaddressed. This novel ovine model of induced CAS can be used in a variety of studies 
regarding human disease pathobiology and be used as a platform to increase treatment efficiency. In 
addition, future studies can be designed to including inoculations of either monomicrobial or 
polymicrobial infections or different types of pathogens (bacterial, fungal, viral), can utilize this in-vivo 
animal model of sepsis. However, preliminary small scale studies needs to be conducted to test sheep’s 





research design can be utilized to induce specific comorbidities in these sheep to test the different 
pathophysiologys in; immunocompromised, diabetic, ketonic, malnourished, genetically diverse, age, 
race and gender to study how they affect the pathophysiology and ways to treat them.  
There are many potential applications to warrant the use of this sheep model of sepsis such as; 
establishing a better understanding of the colonization, adaptation and shedding of carbapenem-resistant 
Enterobacteriaceae (CRE), as well as KPC spread and epidemiology. Additionally, testing new drug 
therapies or optimal drug dosing regimens, studying in-vivo biofilm formation leading to seeding of 
infection and ways to treat and prevent them (49). Likewise, a pre-challenge drug intervention can be 
tested prior to microbial insult to protect certain populations, as well.  
  Conclusion. It’s an undeniable truth that most animal models used in modern research are frequently 
the most convenient model utilized, instead of the best available. However, in order to make clinical 
advancements, the most translatable and reliable animal models ought to be used, and these are often 
non-murine models [4, 18-21, 24]. In sheep, the size, temperament, and ease of catheter (placement and 
maintenance) coupled with aforementioned intrinsic factors shared with humans make them great 
platforms for pre-clinical evaluation and optimization of biomedical and sepsis research.  
This proof of concept study addresses the urgent need for an improved animal model in sepsis 
research. In particular, central catheter associated sepsis which has a complex pathobiology that includes 
biofilm formation and has one of the highest mortality rates in human sepsis. The development of CAS 
depends on several intrinsic and extrinsic factors in both the host and pathogen, characterized by the 
high heterogeneity seen in human and sheep sepsis.  Further, the nonsurgical (no sedation and no general 
anesthesia) model of central catheter placement coupled with seeding catheter lumen with a 
monomicrobial infection and can be housed and tested using both short- and long-term catheter studies. 





biomarkers, vasopressors and intravenous antibiotics, all of which are not feasible in the most common 
mouse model. Lastly, the routine hemodynamic, immunological, coagulation, biochemical and 
microbiological monitoring of these sheep can provide great insight to sepsis pathophysiology and can 
be analyzed in great detail. Future sheep (or other large animal) research models of CAS is warranted to 
further understand this medical enigma we call sepsis.   
An evolved method of effectively diagnosing and categorizing this multifactorial disease processes 
is essential to the improved prognosis of sepsis. As the complex pathophysiology of sepsis and its 
associated syndromes (acute organ injury or dysfunction) become better understood, it is likely that 
sepsis will no longer be considered generalized syndromes with a broad range of clinical symptoms and 
treatments. Rather, each syndrome would contain various sets of well-defined disease subtypes that can 
be characterized by specific cellular changes, clinical symptomologies and/or accompanied biomarkers. 
Each of which can have therapy regimens developed to optimize their efficacy and improve overall 
sepsis survivability.   
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Figure 1. a-f, Control Group vs. Challenge Group #1: various measurements (physiological, 
hematological, and biochemical) taken throughout study. A. Rumen “Core” (Temperatures,  oC), B. 
Heart Rates (BPM), C. Respiratory Rates (/Minute), D. Serum Lactate Concentration (mM), E. 





*Note: varied sample frequency based on Ewe condition, ability to attain viable samples and 
experimental setup. 
Figure 2. a-f, Control Group vs. Challenge Group #2: various measurements (physiological, 
hematological, and biochemical) taken throughout study. A. Rumen “Core” (Temperatures,  oC), B. 
Heart Rates (BPM), C. Respiratory Rates (/Minute), D. Serum Lactate Concentration (mM), E. 
Platelets-Auto (x103/ul), F. Neutrophil Counts (x107/ul). *Note: varied sample frequency based on 
Ewe condition, ability to attain viable samples and experimental setup. See figure 3 for high resolution 
graphs for intensive monitoring data (shaded area in 3.A- 3.D). 
Figure 3. Intensive monitoring for Challenge Group #2 administered highest inoculation Dose, (Dose 
#4 of ~1x109 CFU). Intensive monitoring of thermoregulation and cardiovascular parameters Control 
Group vs. Challenge Group #2: High Dose intensity monitoring of A. Respiratory Rates (Top-Left), B. Heart 
Rates (Top-Right), C. Rumen Temperatures (Bottom-Left), and D. Serum Lactates (Bottom-Right). 
thermoregulation and cardiovascular recorded every 15 minutes during the first hour post inoculation, 
then once an hour thereafter for 5 hours. Rumen Temperatures were sampled every 30 minutes and 
Serum Lactates every 2 hours post high dose administration for 6 hours.  
Figure 4A. Gross pathology sample from Challenge Group #1:4B. Gross pathology samples of two separate 
lung samples from Challenge Group #2 at necropsy 
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Table 1. Ewes in Challenge Group #2; displaying overt DIC Criteria. D-Dimer (ng/ml), PT and PTT 
time (seconds). *Adopted from ISTH algorithm for overt DIC in humans [72, 73, 75, 77, 97, 98]. 1D-
Dimer (ng/ul), 2PT- Prothrombin Time (seconds), 11-13 seconds is the normal range in humans, with 
an international normalized ratio (INR) of: .8-1.1, PT: <3 seconds = 0 points, >3 seconds but 
<6seconds = 1 point, >6 seconds = 2 Points. 3PTT- Partial Thromboplastin Time (Seconds), PTT: 60-
70, 30-40 aPTT (Avg human). Average Platelet Count (x103/ul) Change from Baseline: pre-
inoculation averages of all sheep day -2 through day -1 (n=8, X=16) x ̅= 367 σ= 165. According to the 
International Society of Thrombosis and Homeostasis (ISTH) Platelet count: >100 x 103/ul = 0 pts, 
<100 x103/ul = 1pt, <50x103/ul=2 pts score for DIC in humans [77]. According to this data the mean 
baseline platelet counts for humans and sheep were -Baseline pre-inoculation averages of all sheep day 
-2 through day -1 (n=8, X=16)  ?̅?= 367 σ=  165. Fibrinogen Concentrations (mg/dl) in all Groups.  To 
calculate DIC in humans a value of >1g/L gives a significant hyperfibrinogen and a score of 1 and a 
value of <1g/L gives a score of 0 according to the International Society of Thrombosis and 
Homeostasis (ISTH) score for DIC in humans [77]. Note: values presented in sheep are in mg/dl (a 







Table 2. Severity of sheep sepsis based on both old and new human definitions: (SIRS, SOFA). 1. 
Heart rate mean: 75.88, 2σ=7.78, 2. Respiratory rate mean: 27.02, 2σ= 8.06, 3a. Rumen temperature 
mean: 39.567, 2σ=.413, 3b. Rectal temperature mean: 38.76, 2σ=.33, 4. Lactate concentration mean: 
.66, 2σ: .33, 5. White blood cell count mean: 5.86, 2σ: .74, 6. Neutrophil Mean: 3.09, 2σ: .79. 7. 
Creatinine Mean:  0.869, 2σ: 0.1676 (or +30%: 1.13) **Note: Challenge group #1 (Ewe #’s 1 and 2). 







Appendix I. K. pneumoniae inoculation, Parent Isolate, sample culture results and culture methods 
and inoculation doses/dates. 
 
Appendix II. Histopathology Report. Klebsiella pneumoniae septicemia in ewes. 
 
Appendix III. Monitoring and treatment matrix for sheep IV-sepsis model. 
Appendix IV.  Twice Daily Ewe Evaluation. 
 
Appendix V. Common Human Diagnostic Criteria of Sepsis and Organ Dysfunction Relevant in 
Sheep. 
 
Appendix VI. All Graphs and Tables of Data Analysis. 
Appendix VII. EWE #4 from Challenge group #2: all data plotted 
 
Supplemental Materials. 
- All Graphs and Tables of Data Analysis. 
- All Gross Histology Photos 
-Sheep Placement and outlining group layouts, experimental setup, dose inoculations and day of 
inoculations. 
 
























































































































































































































































































































Figure 3. Control Group vs. Challenge Group #2: High Dose intensity monitoring of A. Respiratory 
Rates (Top-Left), B. Heart Rates (Top-Right), C. Rumen Temperatures (Bottom-Left), and D. Serum 











Figure 4A. Gross pathology sample from Challenge Group #1: 
  
4B. Gross pathology samples of two separate lung samples from Challenge Group #2 at necropsy. 




















of Overt DIC: 
Pre-inoculation 
(N=8) 
Day #2 Average 
(N=3) 
Day #13 Average 
(N=3) 
Day #14  
Average (N=3) 
D-Dimer1 ?̅? = 868 1002 (↑133.18) 1956 (↑1088) 1584 (↑716) 
PT2 
?̅? = 10.15 
σ = 0.778 
12.03 (↑1.88) 16.73 (↑6.58) 14.27 (↑4.12) 
PTT3  
?̅? = 43.26 
σ = 5.995 
40.1 (↓3.16) 60.7 (↑17.44) 56.27 (↑13.01) 
Platelet4 
?̅? = 367 
σ =165 
↓306 ↓133 ↓121 
Fibrinogen5 
?̅?= 350  
σ= 141 




Table 2. Severity of sheep sepsis based on both old and new human definitions (SIRS, SOFA). 
 **See Appendix VI for individual values, averages and inter/intra group comparisons.** 









































Control Group    
(N=2): 
Sterile TSB 
0/2     0/2 1/2     0/2    0/2  0/2   0/2 0/2    0/2    0/2  0/2  0, 0, 0 
Challenge 
Group #1 
Dose # 1: 
~103 CFU 
1/3     3/3 2/3     2/3    2/3  3/3   3/3 3/3    0/3    0/3  0/3  1, 0, 0 
Challenge 
Group #2, 
Dose # 2: 
~107 CFU 
2/3     3/3 2/3     3/3    2/3  3/3   3/3 3/3    0/3    0/3  0/3  0, 0-1, 0-1 
Challenge 
Group #1 
Dose # 3: 
~108 CFU 





3/3     3/3 3/3     3/3    2/3  3/3   3/3 3/3    1/3    2/3  2/3  2-4, ≥5, 1-3  
Heart rate mean: 75.88, 2σ=7.78, 2. Respiratory rate mean: 27.02, 2σ= 8.06, 3a. Rumen temperature mean: 39.567, 2σ=.413, 3b. Rectal temperature mean: 38.76, 2σ=.33,  
4. Lactate concentration mean: .66, 2σ: .33, 5. White blood cell count mean: 5.86, 2σ: .74, 6. Neutrophil Mean: 3.09, 2σ: .79. 7. Creatinine Mean: 0.869, 2σ: 0.1676 (or +30%: 1.13)  
*Note: control group #1 (Ewe #’s 1 and 2) displayed neither SIRS symptoms nor SOFA criteria of sepsis throughout the duration of the study. 
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